Sermorelin is a synthetic 29–amino-acid peptide corresponding to the first 29 residues of human growth hormone-releasing hormone (GHRH), often written as GHRH(1-29) or GRF(1-29). This fragment is the shortest portion of the native 44–amino-acid hormone that retains essentially full biological activity at the GHRH receptor, which is why it has long served as a reference tool for studying the growth hormone (GH) axis in vitro and in animal models. This article summarizes its background, mechanism, and the published research landscape for laboratory research use only.
Research Background
Growth hormone-releasing hormone is produced mainly in the hypothalamus, where it signals the anterior pituitary to synthesize and release growth hormone. GH in turn drives production of insulin-like growth factor 1 (IGF-1), largely in the liver, and influences metabolism, cellular growth, and body composition. Native GHRH exists chiefly as a 44-residue peptide, but structure–activity studies established that the N-terminal 1-29 sequence carries the receptor-binding and activating information; residues beyond position 29 are largely dispensable for potency. Sermorelin is the synthetic acetate salt of this GHRH(1-29) sequence.
A key limitation of the native peptide motivated much of this work: GHRH is degraded rapidly in plasma. Frohman and colleagues showed that human plasma cleaves GHRH between residues 2 and 3, producing the biologically inactive fragment GRH(3-44), with the intact peptide disappearing by high-performance liquid chromatography with a half-life of roughly 17 minutes in vitro (Frohman et al., J Clin Invest, 1986). This dipeptidyl peptidase IV–type cleavage at the N-terminus is the same vulnerability that later analogs such as CJC-1295 and tesamorelin were engineered to resist. Sermorelin shares the native N-terminus and therefore the same short duration of action, which makes it a useful unmodified comparator in stability and metabolism studies.
Mechanism of Action
Sermorelin binds the growth hormone-releasing hormone receptor (GHRHR), a class B G protein-coupled receptor expressed on somatotroph cells of the anterior pituitary. Receptor activation couples through Gs to adenylyl cyclase, raising intracellular cyclic AMP (cAMP). Elevated cAMP activates protein kinase A (PKA), which promotes calcium influx and the transcription and secretion of growth hormone. Because it acts at the same receptor as native GHRH, sermorelin reproduces the physiological signaling of the endogenous hormone rather than bypassing it.
An important feature for experimental models is that sermorelin acts upstream, at the pituitary, leaving downstream feedback intact. GH and IGF-1 negative feedback and somatostatin tone continue to modulate the response, which is why researchers use GHRH(1-29) to probe intact hypothalamic–pituitary regulation rather than to override it. The GHRH receptor is not confined to the pituitary: in vitro work has identified functional GHRH receptors on other cell types. Cui and Schally reported that human and rat hepatocytes express GHRH receptors and that GHRH(1-29)NH2 and GHRH agonists down-regulated IGF-1 mRNA and inhibited IGF-1 secretion in human cancer cell lines, with signaling linked to the JAK2/STAT5 pathway (Cui and Schally, Oncotarget, 2018). Findings like these have broadened interest in GHRH-family peptides as tools for studying receptor biology beyond the classical GH axis.
Published Research Overview
The literature on sermorelin spans several decades. Early human pharmacology characterized its kinetics and potency: Wilton and colleagues administered GHRH(1-29)-NH2 to healthy adult volunteers and reported a short plasma half-life of approximately 11–12 minutes, dose-dependent GH release beginning at intravenous doses as low as 0.25 µg/kg with maximal release near 1–2 µg/kg, and low nasal bioavailability of about 3–5% (Wilton et al., Acta Paediatrica, 1993). A comprehensive review by Prakash and Goa cataloged its use as a diagnostic probe of pituitary GH reserve and summarized its receptor pharmacology and safety profile in the historical clinical literature (Prakash and Goa, BioDrugs, 1999).
More recent work has focused on analytical chemistry and metabolism. Memdouh and colleagues studied the in vitro metabolism of four larger GHRH-family analogs, including sermorelin, in fortified urine, identifying characteristic metabolites such as sermorelin(3-29)-NH2 and developing liquid chromatography–tandem mass spectrometry methods with detection limits near 1 ng/mL (Memdouh et al., Drug Test Anal, 2021). As of 2024, review articles continue to place GHRH(1-29) within the broader development of GHRH analogs for research in metabolism, regenerative biology, and oncology, underscoring that the unmodified 1-29 sequence remains the mechanistic baseline against which longer-acting engineered analogs are compared (Cai et al., Rev Endocr Metab Disord, 2024).
How does sermorelin differ from other GHRH analogs?
Sermorelin is the native GHRH(1-29) sequence with no stabilizing modifications. Analogs such as tesamorelin add a chemical group to slow degradation, while CJC-1295 attaches to albumin (via a drug affinity complex in one version) to greatly extend half-life. Because sermorelin retains the native, DPP-IV–susceptible N-terminus, it has a much shorter duration of action, which is precisely why it is valued as an unmodified reference compound in comparative stability, metabolism, and receptor-signaling studies.
Storage & Handling
Dynamite Research Peptides supplies Sermorelin in lyophilized (freeze-dried) form. Store the powder at -20°C, protected from light and moisture. Reconstitute immediately before use with an appropriate sterile solvent following standard laboratory protocols, and avoid repeated freeze-thaw cycles, which can degrade peptide integrity. Handle with appropriate personal protective equipment (gloves, eye protection, lab coat) in a well-ventilated laboratory area. High-purity material shipped with a Certificate of Analysis (COA) supports reproducible in-vitro results.
Conclusion
Sermorelin, the synthetic GHRH(1-29) fragment, is a well-characterized tool for studying the growth hormone axis. As the shortest fully active portion of native GHRH, it activates the GHRHR–cAMP–PKA pathway while preserving the natural feedback architecture of the system, making it a standard mechanistic reference for research on GH regulation, peptide stability, and GHRH receptor signaling. Its short, native-sequence half-life is exactly what makes it useful as a comparator for engineered long-acting analogs.
All products are for research use only (RUO) — not for human or animal consumption, and not for diagnostic or therapeutic use. Nothing in this article should be interpreted as medical guidance or as a description of any intended effect in humans.
Frequently Asked Questions
What is sermorelin?
Sermorelin is a synthetic peptide made up of the first 29 amino acids of human growth hormone-releasing hormone, GHRH(1-29). It is the shortest fragment of native GHRH that retains full activity at the GHRH receptor and is used as a research reference compound for the growth hormone axis.
How does sermorelin work at the molecular level?
It binds the GHRH receptor on pituitary somatotroph cells, a Gs-coupled GPCR that activates adenylyl cyclase, raises cyclic AMP, and engages protein kinase A to drive growth hormone transcription and secretion. It acts upstream at the pituitary, leaving GH/IGF-1 feedback intact.
Why does sermorelin have such a short half-life?
Its native N-terminus is cleaved between residues 2 and 3 by dipeptidyl peptidase IV–type activity in plasma, producing an inactive fragment. Reported plasma half-life is roughly 11–12 minutes, which is why engineered analogs modify this region to extend duration.
How should sermorelin be handled in the laboratory?
Store lyophilized peptide at -20°C away from light and moisture, reconstitute immediately before use, avoid repeated freeze-thaw cycles, and use standard PPE. For research use only — not for human or animal consumption.
Last updated: July 10, 2026.